Data from EMC - Curated by Toby Galbraith - Last updated 24 April 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types.

The use of Cervarix should be in accordance with official recommendations.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines

Visit Cystic Fibrosis

More information

Category Value
Agency product number EMEA/H/C/000721
Orphan designation No
Date First Approved 20-09-2007
Type Medicinal product subject to medical prescription
Marketing authorisation holder GlaxoSmithKline Biologicals S.A.

Related Content